Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

trust,dog

ICYMI: A Shortage of Trust

I wanted to complain about patients who complain, but guilt and common sense took over. I intended to declare the problem to primarily belong to the doctor, rather than the patient. To me, the solution to the patient’s consternation should begin and end with the source: me (you). My introspection, reasonings, and commandments were fine, but I kept running into the enigma of “Trust” – which can either be a speed-bump or chasm in our physician-patient relationships.

Read Article
ChatGPT,computer,learning

ICYMI: ChatGPT - A Boon or Threat to Scientific Publication?

ChatGPT is a new, artificial intelligence chatbot that has dramatically changed the digital worlds of education, research, graphic design, statistics and more. While this AI driven platform has the untold potential in generating written content, there is considerable concern in assuring that human-generated content of research, education and publishing has veracity.

Read Article
inflammati.png

ICYMI: LAVLI - A New Autoinflammatory Disorder

NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic inflammation, by altering microvascular permeability and neutrophil recruitment, while at the same time promoting hepatic fibrosis.

Read Article
computer screen safety

ICYMI: Drug Safety Differences with New Novel Therapies in RA

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.

Read Article
Achilles,ankle,heel

ICYMI: GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis

GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. 

Read Article
eye%20exa.jpg (keep)

ICYMI: Hydroxychloroquine Dose and Risk for Incident Retinopathy

A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy. The study aimed to assess the long-term risk for incident hydroxychloroquine retinopathy and examine the degree to which average hydroxychloroquine dose within the first 5 years of treatment predicts this risk.

Read Article
Giants,women,rheumatology

ICYMI: 25 Great Women in Rheumatology

I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

ICYMI: Carpal Tunnel - Steroid injection vs. Night Splinting

A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.

Read Article
ANA.Wikipedia.jpg (keep)

ICYMI: New Laboratory Insights for the ANA+ Consult

A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).

Read Article
alcohol%20glasses-919071__180.jpg (keep)

ICYMI: RA Disease Activity and Alcohol Use

Despite its well known toxicities, alcohol is known to be antiinflammatory. The effects of alcohol use in rheumatoid arthritis (RA) is less known, but a recent study suggests that alcohol consumption was dose-dependently associated with lower disease activity and higher health-related quality of life in RA patients.

Read Article
×